Patent 12013326

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2023-11-10 · recorded 2023-11-30 · reel 006240/0173 · Assignment

    O'RIORDAN, CATHERINE; BURNHAM, BRENDAGENZYME CORPORATION

    Correspondent: BETH D. GOLDMAN · SANOFISHARE

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Catherine R. O'Riordan (Genzyme Corp)
  • Brenda BURNHAM (Genzyme Corp)

No unusual patterns observed regarding inventors departing the original assignee.

Original assignee

The entity named on the issued patent is Genzyme Corp. Genzyme Corp is a biotechnology company that develops and manufactures products for rare diseases. As of today's date, Genzyme Corp operates as a subsidiary of Sanofi, having been acquired in 2011.

Assignment timeline

  • 2023-11-10 (executed) / recorded 2023-11-30 — Reel 006240/0173
    • Conveyance: Assignment
    • Assignor: O'RIORDAN, CATHERINE; BURNHAM, BRENDA
    • Assignee: GENZYME CORPORATION
    • Correspondent: BETH D. GOLDMAN, SANOFISHARE, 50 BINNEY STREET, CAMBRIDGE, MA, UNITED STATES, 02142
    • Context: Inventors assigned their interest to the original assignee.

Timeline diagram

timeline
    title Ownership of US 12013326
    2023 : Inventors assigned to Genzyme Corp
    2024 : Patent granted

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. The sole assignee beyond the inventors is Genzyme Corporation, a known operating company.
  2. Known asserter in the chain — not present. Genzyme Corporation is not listed as a known patent asserter.
  3. Repeat correspondent across the chain — not present. Only one assignment is recorded, and thus no recurrence can be observed.
  4. Cascading transfers — not present. Only one assignment is recorded.
  5. Pre-litigation transfer — unclear. While there is an IPR filing (IPR2026-00149), the patent was granted on 2024-06-18 and the single assignment was recorded on 2023-11-30. The IPR was filed in 2026, which is more than 6 months after the assignment.
  6. Bankruptcy fire-sale — not present. There is no indication of Genzyme Corp or Sanofi being in bankruptcy.
  7. Privateering — not present. No evidence of privateering.
  8. Defensive aggregator (anti-NPE) — not present. The chain does not terminate at a known defensive aggregator.

Verdict

Insufficient data. There is only one recorded assignment, which is from the inventors to the original assignee, Genzyme Corp. This transfer is standard practice and does not provide enough information to identify any NPE or patent-troll patterns.

Verification: https://assignmentcenter.uspto.gov/

Generated 5/27/2026, 6:46:03 AM